Report overview
Short bowel syndrome (SBS) is a metabolic disorder occurs when the portion of the small intestine is not functioning or removed through surgery due to digestive illness. SBS is caused by lack of function of the small intestine. This results in malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition.
This report aims to provide a comprehensive presentation of the global market for Short Bowel Syndrome (SBS) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Short Bowel Syndrome (SBS) Drugs. This report contains market size and forecasts of Short Bowel Syndrome (SBS) Drugs in global, including the following market information:
Global Short Bowel Syndrome (SBS) Drugs Market Revenue, 2019-2024, 2024-2029, ($ millions)
Global Short Bowel Syndrome (SBS) Drugs Market Sales, 2019-2024, 2024-2029, (K Pcs)
Global top five Short Bowel Syndrome (SBS) Drugs companies in 2023 (%)
The global Short Bowel Syndrome (SBS) Drugs market was valued at US$ million in 2023 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
During 2017, the parental route segment accounted for the major shares and dominated the SBS market. Factors such as the rapid action mechanism of the drug and the prolonged action result contribute to the growth of this market segment in the coming years. In the parental route, the drug is administered intravenously, subcutaneously, intrathecally, or through intramuscular routes and is applied when the oral route of drug administration is ineffective.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Short Bowel Syndrome (SBS) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Short Bowel Syndrome (SBS) Drugs Market, by Type, 2019-2024, 2024-2029 ($ Millions) & (K Pcs)
Global Short Bowel Syndrome (SBS) Drugs Market Segment Percentages, by Type, 2023 (%)
Glucagon-Like Peptide-2 (GLP-2)
Growth Hormone
Glutamine
Other
Global Short Bowel Syndrome (SBS) Drugs Market, by Sale Channel, 2019-2024, 2024-2029 ($ Millions) & (K Pcs)
Global Short Bowel Syndrome (SBS) Drugs Market Segment Percentages, by Sale Channel, 2023 (%)
Hospitals
Clinics
Retail Pharmacies
Global Short Bowel Syndrome (SBS) Drugs Market, By Region and Country, 2019-2024, 2024-2029 ($ Millions) & (K Pcs)
Global Short Bowel Syndrome (SBS) Drugs Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Short Bowel Syndrome (SBS) Drugs revenues in global market, 2019-2024 (Estimated), ($ millions)
Key companies Short Bowel Syndrome (SBS) Drugs revenues share in global market, 2023 (%)
Key companies Short Bowel Syndrome (SBS) Drugs sales in global market, 2019-2024 (Estimated), (K Pcs)
Key companies Short Bowel Syndrome (SBS) Drugs sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Takeda
Emmaus Medical
Ardelyx
Naia Pharmaceuticals
Nutrinia
OxThera
Sancilio Pharmaceuticals
Zealand Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Short Bowel Syndrome (SBS) Drugs, market overview.
Chapter 2: Global Short Bowel Syndrome (SBS) Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Short Bowel Syndrome (SBS) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by sale channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Short Bowel Syndrome (SBS) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Short Bowel Syndrome (SBS) Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
